{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:13344"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:13344","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Engineering CAR-T cells to overcome the immunosuppressive microenvironment of solid tumours","abstract":"Chimeric antigen receptor (CAR)-T cell therapies have revolutionised the treatment landscape for cancer patients. However, engineered adoptive lymphocyte-based therapies face significant resistance in solid tumour microenvironments due to amino acid and nutrient scarcity, as well as significant infiltration of suppressive myeloid cells. Here, we investigated the microenvironment of different solid tumours and assessed the detrimental effects of myeloid-derived suppressor cells (MDSCs) on the autologous and engineered anti-cancer immunity. We demonstrated a novel strategy to improve CAR-T cell efficacy and tumour clearance by depleting MDSCs with a repurposed CD33-directed immunoconjugate, Gemtuzumab Ozogamicin. In addition, we designed metabolically enhanced CAR-T cell constructs, to endow the T cells with increased L-arginine catabolic activity. We found that arginase-transduced CAR-T cells were able to recognise and lyse target cells in a comparable fashion to the anti-GD2 control. However, they presented an enhanced bioenergetic flexibility, evidenced by the increased maximal respiration achieved during the MitoStress test (p = 0.010), and a higher intracellular abundance of key metabolites, such as pyruvate (p = 0.028) and glutamine (p = 0.003). Ultimately, the novel CAR-T cells were shown to have a proliferative advantage upon antigen stimulation (p = 0.015) and induce superior tumour reduction in vivo (p = 0.010) compared to the standard CAR-T cells.","abstract_html":"Chimeric antigen receptor (CAR)-T cell therapies have revolutionised the treatment landscape for cancer patients. However, engineered adoptive lymphocyte-based therapies face significant resistance in solid tumour microenvironments due to amino acid and nutrient scarcity, as well as significant infiltration of suppressive myeloid cells. Here, we investigated the microenvironment of different solid tumours and assessed the detrimental effects of myeloid-derived suppressor cells (MDSCs) on the autologous and engineered anti-cancer immunity. We demonstrated a novel strategy to improve CAR-T cell efficacy and tumour clearance by depleting MDSCs with a repurposed CD33-directed immunoconjugate, Gemtuzumab Ozogamicin. In addition, we designed metabolically enhanced CAR-T cell constructs, to endow the T cells with increased L-arginine catabolic activity. We found that arginase-transduced CAR-T cells were able to recognise and lyse target cells in a comparable fashion to the anti-GD2 control. However, they presented an enhanced bioenergetic flexibility, evidenced by the increased maximal respiration achieved during the MitoStress test (p = 0.010), and a higher intracellular abundance of key metabolites, such as pyruvate (p = 0.028) and glutamine (p = 0.003). Ultimately, the novel CAR-T cells were shown to have a proliferative advantage upon antigen stimulation (p = 0.015) and induce superior tumour reduction in vivo (p = 0.010) compared to the standard CAR-T cells.","abstract_has_math":false,"creators":["Panetti, Silvia"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2023,"date_issued":"2023-07","date_published":"2023-07","updated_at":"2026-11-19T09:32:17Z","subjects":["QH301 Biology","QR180 Immunology"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[{"key":"person:identifier.orcid","label":"ORCID","values":["0000000301767636"],"render_values":[{"text":"0000-0003-0176-7636","href":"https://orcid.org/0000-0003-0176-7636","code":true}]}]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/13344/7/Panetti2023PhD_Redacted.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A13344","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["other"]},{"key":"dc:creator","label":"Author","values":["Panetti, Silvia"]},{"key":"person:identifier.orcid","label":"ORCID","values":["0000000301767636"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2023-07-14"]},{"key":"dc:date.issued","label":"Date","values":["2023-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/13344/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["QH301 Biology","QR180 Immunology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/13344/7/Panetti2023PhD_Redacted.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Chimeric antigen receptor (CAR)-T cell therapies have revolutionised the treatment landscape for cancer patients. However, engineered adoptive lymphocyte-based therapies face significant resistance in solid tumour microenvironments due to amino acid and nutrient scarcity, as well as significant infiltration of suppressive myeloid cells. Here, we investigated the microenvironment of different solid tumours and assessed the detrimental effects of myeloid-derived suppressor cells (MDSCs) on the autologous and engineered anti-cancer immunity. We demonstrated a novel strategy to improve CAR-T cell efficacy and tumour clearance by depleting MDSCs with a repurposed CD33-directed immunoconjugate, Gemtuzumab Ozogamicin. In addition, we designed metabolically enhanced CAR-T cell constructs, to endow the T cells with increased L-arginine catabolic activity. We found that arginase-transduced CAR-T cells were able to recognise and lyse target cells in a comparable fashion to the anti-GD2 control. However, they presented an enhanced bioenergetic flexibility, evidenced by the increased maximal respiration achieved during the MitoStress test (p = 0.010), and a higher intracellular abundance of key metabolites, such as pyruvate (p = 0.028) and glutamine (p = 0.003). Ultimately, the novel CAR-T cells were shown to have a proliferative advantage upon antigen stimulation (p = 0.015) and induce superior tumour reduction in vivo (p = 0.010) compared to the standard CAR-T cells."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Engineering CAR-T cells to overcome the immunosuppressive microenvironment of solid tumours"]}]}],"canonical_facts":{"dc:contributor.sponsor":["other"],"dc:creator":["Panetti, Silvia"],"dc:date":["2023-07-14"],"dc:date.issued":["2023-07"],"dc:description.abstract":["Chimeric antigen receptor (CAR)-T cell therapies have revolutionised the treatment landscape for cancer patients. However, engineered adoptive lymphocyte-based therapies face significant resistance in solid tumour microenvironments due to amino acid and nutrient scarcity, as well as significant infiltration of suppressive myeloid cells. Here, we investigated the microenvironment of different solid tumours and assessed the detrimental effects of myeloid-derived suppressor cells (MDSCs) on the autologous and engineered anti-cancer immunity. We demonstrated a novel strategy to improve CAR-T cell efficacy and tumour clearance by depleting MDSCs with a repurposed CD33-directed immunoconjugate, Gemtuzumab Ozogamicin. In addition, we designed metabolically enhanced CAR-T cell constructs, to endow the T cells with increased L-arginine catabolic activity. We found that arginase-transduced CAR-T cells were able to recognise and lyse target cells in a comparable fashion to the anti-GD2 control. However, they presented an enhanced bioenergetic flexibility, evidenced by the increased maximal respiration achieved during the MitoStress test (p = 0.010), and a higher intracellular abundance of key metabolites, such as pyruvate (p = 0.028) and glutamine (p = 0.003). Ultimately, the novel CAR-T cells were shown to have a proliferative advantage upon antigen stimulation (p = 0.015) and induce superior tumour reduction in vivo (p = 0.010) compared to the standard CAR-T cells."],"dc:format":["text"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/13344/7/Panetti2023PhD_Redacted.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/13344/"],"dc:subject":["QH301 Biology","QR180 Immunology"],"dcterms:accessrights":["public"],"dc:title":["Engineering CAR-T cells to overcome the immunosuppressive microenvironment of solid tumours"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"],"person:identifier.orcid":["0000000301767636"]},"updated_at":"2026-11-19T09:32:17Z"}